未找到相关数据
A phase I/II study of safety and efficacy of orteronel (TAK-700), an oral, investigational, nonsteroidal 17,20-lyase inhibitor, with docetaxel and prednisone (DP) in metastatic castration-resistant prostate cancer (mCRPC): Updated phase II results
被引：23
作者：
Petrylak, Daniel
Gandhi, Jitendra G.
Clark, William R.
Heath, Elisabeth I.
Lin, Jianqing
Oh, William K.
Agus, David B.
Carthon, Bradley Curtis
Moran, Susan
Kong, Ning
Suri, Ajit
Bargfrede, Michael
Liu, Glenn
机构：
[1] Columbia Univ, Med Ctr, New York, NY USA
[2] Associates Oncol & Hematol, Chattanooga, TN USA
[3] Alaska Clin Res Ctr, Anchorage, AK USA
[4] Karmanos Canc Inst, Detroit, MI USA
[5] Thomas Jefferson Univ, Philadelphia, PA 19107 USA
[6] Mt Sinai Sch Med, Tisch Canc Inst, New York, NY USA
[7] Univ So Calif, Keck Sch Med, Beverly Hills, CA USA
[8] Emory Univ, Winship Canc Inst, Atlanta, GA 30322 USA
[9] Millennium Pharmaceut Inc, Cambridge, MA USA
[10] Univ Wisconsin, Carbone Canc Ctr, Madison, WI USA
关键词：
D O I：
10.1200/jco.2013.31.6_suppl.59
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
59
引用
收藏
页数：1
相关论文